H.R. 1051 · 119th Congress · Health
To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
What it does
The Congressional Research Service hasn’t published a summary of this bill yet. Summaries usually follow within a few weeks of introduction.
Roll call votes
No recorded roll call votes on this bill. Most bills never get one; many pass by voice vote or unanimous consent, or stay in committee.
Latest action
Feb 6, 2025 · Referred to the House Committee on Energy and Commerce.